Insider Buying: Enovis (NYSE:ENOV) Director Purchases $25,108.20 in Stock

Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor bought 870 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average cost of $28.86 per share, with a total value of $25,108.20. Following the completion of the transaction, the director owned 33,243 shares of the company’s stock, valued at $959,392.98. This represents a 2.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Enovis Stock Up 0.4%

Shares of ENOV traded up $0.10 on Friday, reaching $27.74. The company’s stock had a trading volume of 1,205,392 shares, compared to its average volume of 1,879,055. Enovis Corporation has a twelve month low of $16.70 and a twelve month high of $31.67. The stock has a market capitalization of $1.60 billion, a PE ratio of -3.01 and a beta of 1.31. The company has a current ratio of 2.15, a quick ratio of 1.08 and a debt-to-equity ratio of 0.82. The firm has a fifty day moving average of $20.52 and a 200-day moving average of $23.22.

Enovis (NYSE:ENOV – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The company’s quarterly revenue was up 1.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS. Equities analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ENOV. BMO Capital Markets set a $27.00 price target on Enovis in a report on Tuesday, September 1st. Citigroup restated a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. BTIG Research lifted their price objective on shares of Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Needham & Company LLC lifted their price objective on shares of Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Wells Fargo & Company upped their target price on shares of Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus target price of $38.62.

View Our Latest Report on Enovis

Hedge Funds Weigh In On Enovis

Several hedge funds have recently modified their holdings of the company. Marshall Wace LLP boosted its stake in shares of Enovis by 54.2% in the 3rd quarter. Marshall Wace LLP now owns 454,094 shares of the company’s stock worth $8,296,000 after buying an additional 159,649 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Enovis in the third quarter valued at approximately $2,244,000. First Trust Advisors LP grew its holdings in shares of Enovis by 60.2% in the third quarter. First Trust Advisors LP now owns 100,117 shares of the company’s stock valued at $1,829,000 after acquiring an additional 37,636 shares in the last quarter. Public Sector Pension Investment Board increased its position in shares of Enovis by 66.0% during the third quarter. Public Sector Pension Investment Board now owns 328,148 shares of the company’s stock valued at $6,223,000 after acquiring an additional 130,436 shares during the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Enovis by 477.1% during the third quarter. Intech Investment Management LLC now owns 70,796 shares of the company’s stock valued at $1,293,000 after acquiring an additional 58,528 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Latest Enovis News

Here’s some of the latest news about ENOV:

  • Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
  • Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement

Enovis Company Profile

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Recommended Stories

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.